St. Louis, MO, United States of America

Dikla G Roufa

This inventor holds 1 USPTO granted patent. Top assignee: G.d. Searle & Company. Active years: 1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dikla G Roufa. Retrieved from https://idiyas.com/inventor/dikla-g-roufa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 622(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dikla G. Roufa: Inventor in Controlled-Release Formulations

Introduction

Dikla G. Roufa is an inventor associated with St. Louis, Missouri, and G.D. Searle & Company. Her patent work concerns controlled delivery of trophic factors, including nerve growth factor.

Latest Patents

Roufa is credited with 1 patent: “Controlled Release Formulations of Trophic Factors.” The patent describes a formulation for systemic delivery and controlled release of a trophic factor. It uses a glycolipid carrier to deliver the factor to a target organ and protect it from degradation by enzymes naturally present in the human body.

Career Highlights

Roufa’s listed invention focuses on a drug-delivery approach designed to preserve trophic factors and support their controlled release. The patent identifies nerve growth factor as an example of a trophic factor that may be delivered using the formulation.

Collaborations

Roufa’s listed coworkers include Kanaiyalal R. Patel and Lucia G. Marshall. Her patent is associated with G.D. Searle & Company.

Conclusion

Dikla G. Roufa’s patent highlights a glycolipid-based approach to protecting and delivering trophic factors through controlled release.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…